NanoPhoria Bioscience Secures €83.5 Million Series A to Advance Heart Failure Therapy

NanoPhoria Bioscience has successfully secured the first tranche of its €83.5 million Series A financing round. The round was led by Xgen Venture, Sofinnova Partners, and CDP Venture Capital, with participation from Panakes Partners, marking the largest investment ever raised by a biotech startup in Italy.

Record-Breaking Funding Round in Italian Biotech

“This investment aligns with Xgen Venture’s strategy of leading early-stage financing rounds for the most innovative Italian startups addressing real medical needs,” stated Paolo Fundarò, managing partner at Xgen Venture.

“NanoPhoria’s science presents a novel and tangible approach to delivering highly potent therapies directly to the heart, and we are excited to collaborate with such a strong group of investors.” Xgen is investing through its first fund, the Xgen Venture Life Science Fund, launched in 2022 to focus on early-stage biotechnology, medical device, and diagnostics investments.

NanoPhoria is developing pioneering therapeutic solutions targeting cardiovascular and chronic diseases

The newly raised capital will primarily support the development of its lead candidate, NP-MP1. This includes advancing preclinical studies necessary to qualify for Investigational New Drug (IND) status with the U.S. Food and Drug Administration, as well as progressing into early clinical development phases.

“This funding allows us to accelerate the clinical development of NP-MP1 and broaden our therapeutic pipeline,” said Claudio De Luca, CEO and co-founder of NanoPhoria.

“Our innovative delivery platform enables us to reach previously inaccessible cellular targets in cardiomyocytes, bringing us closer to providing life-changing treatments for patients suffering from serious cardiac and chronic diseases that are often inadequately treated by current therapies. We are deeply grateful to our scientific founders, investors, the Board of Directors, and our President, Suman Shirodkar, whose vision and dedication have driven NanoPhoria’s growth and ambition.”

Innovative Lung-to-Heart Delivery Platform

The company’s flagship drug, NP-MP1, represents a new therapeutic approach for heart failure treatment. Delivered through NanoPhoria’s proprietary nano-in-micro lung-to-heart technology, NP-MP1 has shown strong efficacy in preclinical models of heart failure.

The therapy aims to address one of the key underlying causes of heart failure with reduced ejection fraction (HFrEF) by enhancing cardiac contractility. HFrEF affects millions of patients globally and carries a five-year mortality rate of around 40%. NanoPhoria’s breakthrough technology and targeted delivery system offer a promising step forward in tackling one of the most pressing challenges in cardiovascular medicine.

__

(Featured image by Marek Studzinski via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in StartupItalia. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.